feed,title,long_url,short_url
Benzinga,"BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22",https://benzinga.com/general/biotech/21/07/21998080/biomarin-expects-emas-chmp-opinion-in-1h-2022-for-its-hemophilia-a-gene-therapy-fda-resubmission-,https://j.mp/3ifkV0g
